scout
News|Videos|January 20, 2023

Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLL

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME